Clinical Trial Update: Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese participants with chronic genotype 1 hepatitis C infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Ledipasvir (sofosbuvir/ledipasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic HCV Infection | Phase 3 | Status: COMPLETED | Results posted: 2015-06-26